| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | AIP1; API2; BIRC3; CIAP2; HAIP1; IAP homolog C ;RNF49; MIHC; MALT2; Apoptosis inhibitor 2;IAP2;;BIRC3 |
| WB Predicted band size | Calculated MW: 68 kDa ; Observed MW: 72 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human BIRC3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于IAP2(BIRC3)抗体的3篇假设性参考文献示例，供参考：
---
1. **文献名称**：*Development of a High-Affinity Monoclonal Antibody Specific to Human IAP2 for Cancer Biomarker Analysis*
**作者**：Zhang et al.
**摘要**：研究团队开发了一种针对人源IAP2的新型单克隆抗体，通过免疫印迹和免疫组化验证其特异性，证明其在结直肠癌组织中高表达，并与患者预后不良相关。
2. **文献名称**：*IAP2 Antibody-Based Inhibition of NF-κB Signaling Attenuates Inflammatory Responses in Macrophages*
**作者**：Chen et al.
**摘要**：利用IAP2抗体阻断其功能，发现IAP2通过调控NF-κB通路影响巨噬细胞的炎症反应，提示该抗体在治疗自身免疫疾病中的潜在价值。
3. **文献名称**：*A Neutralizing IAP2 Antibody Enhances Chemosensitivity in Triple-Negative Breast Cancer Models*
**作者**：Rodriguez et al.
**摘要**：研究证明靶向IAP2的中和抗体可抑制肿瘤细胞存活，与化疗药物联用显著提高三阴性乳腺癌小鼠模型的治疗效果，为联合疗法提供实验依据。
---
**注**：以上文献为示例，实际引用需通过学术数据库检索真实发表的研究。建议使用关键词“IAP2/BIRC3 antibody”或“IAP2 inhibitor”在PubMed、Web of Science等平台查找。
IAP2 (Inhibitor of Apoptosis Protein 2), also known as BIRC3. is a member of the apoptosis-regulating IAP family, which plays critical roles in cell survival, inflammation, and immune response. Structurally, IAP2 contains three baculovirus IAP repeat (BIR) domains that mediate protein-protein interactions and a C-terminal RING domain with E3 ubiquitin ligase activity. It inhibits apoptosis by binding to and suppressing caspases, particularly caspase-3 and -7. while also modulating NF-κB signaling pathways to promote cell survival and inflammatory responses.
IAP2 is overexpressed in various cancers, autoimmune disorders, and inflammatory diseases, contributing to tumor progression, therapy resistance, and chronic inflammation. Its dysregulation is linked to poor prognosis in malignancies like lymphoma and leukemia. Antibodies targeting IAP2 are valuable tools for detecting its expression in research (e.g., Western blot, immunohistochemistry) and exploring its functional mechanisms. Therapeutically, IAP2 antibodies or related inhibitors (e.g., SMAC mimetics) are under investigation to counteract IAP2’s anti-apoptotic effects, aiming to restore cell death in cancer cells or modulate immune responses. However, challenges remain in balancing efficacy with potential off-target effects due to structural similarities among IAP family members.
×
